Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required.

@article{Pascual2009RevisionOT,
  title={Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required.},
  author={Ana Maria Pascual and Neus T{\'e}llez and Isabel Bosc{\'a} and Javier Mallada and Antonio Belenguer and Inmaculada Abell{\'a}n and Angel P{\'e}rez Sempere and Pascual Fern{\'a}ndez and Ma Jos{\'e} Magraner and Francisco Coret and Miguel Angel Sanz and Xavier Montalban and Bonaventura Casanova},
  journal={Multiple sclerosis},
  year={2009},
  volume={15 11},
  pages={1303-10}
}
The objective in this paper is to compare the cumulative incidence and incidence density of therapy-related acute myeloid leukaemia in two cohorts of patients with multiple sclerosis treated with mitoxantrone, and with previously reported data in the literature. Six new cases of acute myeloid leukaemia were observed by prospectively following two Spanish series of 142 and 88 patients with worsening relapsing multiple sclerosis and secondary-progressive disease treated with mitoxantrone. A… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 23 extracted citations

Similar Papers

Loading similar papers…